Show simple item record

AdvisorAl-Badriyeh, Daoud
AuthorAl-Shaibi, Samaher Mohammad Ali
Available date2021-07-06T05:38:43Z
Publication Date2021-06
URIhttp://hdl.handle.net/10576/21222
AbstractObjective: This thesis sought to evaluate the cost-effectiveness of oral paracetamol and intravenous (IV) indomethacin as alternatives to ibuprofen for patent ductus arteriosus (PDA) in neonates in Hamad Medical Corporation (HMC), Qatar. Methods: Decision-analytic, literature-based, economic simulation models were constructed, from the hospital perspective, to evaluate oral/IV ibuprofen versus IV indomethacin, and oral/IV ibuprofen versus oral paracetamol, as first-line therapies for PDA closure. Cost model inputs were HMC based, and therapy success was defined as PDA closure with/without adverse events. Results: Oral ibuprofen is dominant/cost-effective over IV indomethacin in 92% of simulated cases, but oral paracetamol was 82% dominant/cost-effective over oral ibuprofen. Against IV ibuprofen, IV indomethacin was 59% dominant/cost-effective, whereas oral paracetamol was dominant/cost-effective in 91% of the cases. Sensitivity analyses confirmed the study's robustness. Conclusion: For PDA closure, while IV indomethacin was cost-effective against IV ibuprofen, oral paracetamol was cost-effective against both oral and IV ibuprofen.
Languageen
SubjectIbuprofen
Indomethacin
Paracetamol
Patent Ductus Arteriosus
Neonates
Hamad Medical Corporation (HMC)
TitleCost-effectiveness Analysis of Ibuprofen versus Indomethacin or Paracetamol for the Treatment of Patent Ductus Arteriosus in Preterm Neonates
TypeMaster Thesis
DepartmentPharmacy
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record